[Colon cancer at the National Institiue of Nutrition. I. Treatment results from 1979 to 1989].
OBJECTIVE
To establish the resectability, overall survival, perioperative morbidity and mortality and response to adjuvant chemotherapy during the period 1979-1989 at the Instituto Nacional de la Nutrición Salvador Zubirán for patients with carcinoma of the colon retrospectively reviewed.


RESULTS
One hundred and thirty two patients were staged according to Dukes-Astler as follows: 6 in stage A, 7 in B1, 45 in B2, 33 in C and 41 in D. Surgery was performed on 91 patients (69%) for curative purposes and in 31 for palliative purposes. No surgical procedure was possible on 10 of the cases. Postsurgery morbidity was found in 25% of the cases: the most frequent were intraabdominal infection, fistula formation, and dehiscence of the enteral anastomosis. The surgical mortality was 9.6%. The actuarial survival at 8 years is 90% for patients in stages A and B1, 75% for stage B2, and 30% for stage C. In 47 patients in stages B2 and C, adjuvant chemotherapy was administered as follows: FAM regimen in 12; FABcnu in 14; MTX/5FU (sequential) in 14; and other in 7 cases; 35 individuals did not receive adjuvant chemotherapy (13 were in stage B1 and 22 in stages B2 and C). There was no significant difference in survival for this last group versus those with chemotherapy but the patients with MTX-5FU showed a longer survival (82%) and FAM (77%) as compared with surgery only (61%) at five years of diagnosis.


CONCLUSIONS
In our experience 70% of the cases were resectable at the time of diagnosis. Perioperative morbidity and mortality were similar to those reported in the literature. Given the retrospective character of our study, our conclusions on adjuvant chemotherapy are not definitive.
León-Rodríguez
E
E
Servicio de Hemato-oncología, Instituto Nacional de la Nutrición Salvador Zubirán, México, D.F.
Candelaria Hernández
M
M
D000047:Academies and Institutes; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002330:Carmustine / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant / Q000706:statistics & numerical data; D003082:Colectomy / Q000706:statistics & numerical data; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery; D003125:Colostomy / Q000706:statistics & numerical data; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D015993:Life Tables; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008800:Mexico / Q000453:epidemiology; D016685:Mitomycin / Q000008:administration & dosage; D009367:Neoplasm Staging; D010166:Palliative Care / Q000706:statistics & numerical data; D011183:Postoperative Complications / Q000453:epidemiology; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil; D002330:Carmustine; D008727:Methotrexate
Cáncer de colon en el Instituto Nacional de la Nutrición. I. Resultados del tratamiento de 1979 a 1989.